| Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection C Fiala, EP Diamandis BMC medicine 16, 1-10, 2018 | 235 | 2018 |
| The challenges and mental health issues of academic trainees R Eleftheriades, C Fiala, MD Pasic F1000Research 9, 2020 | 92 | 2020 |
| Can circulating tumor DNA be used for direct and early stage cancer detection? EP Diamandis, C Fiala F1000Research 6, 2017 | 50 | 2017 |
| Circulating tumor DNA for early cancer detection C Fiala, V Kulasingam, EP Diamandis The Journal of Applied Laboratory Medicine 3 (2), 300-313, 2018 | 40 | 2018 |
| Pitfalls in cancer biomarker discovery and validation with emphasis on circulating tumor DNA AH Ren, CA Fiala, EP Diamandis, V Kulasingam Cancer Epidemiology, Biomarkers & Prevention 29 (12), 2568-2574, 2020 | 33 | 2020 |
| The meteoric rise and dramatic fall of Theranos: lessons learned for the diagnostic industry C Fiala, EP Diamandis Clinical Chemistry and Laboratory Medicine (CCLM) 56 (9), 1443-1446, 2018 | 25 | 2018 |
| New approaches for detecting cancer with circulating cell-free DNA C Fiala, EP Diamandis BMC medicine 17, 1-3, 2019 | 24 | 2019 |
| P4 medicine or O4 medicine? Hippocrates provides the answer C Fiala, J Taher, EP Diamandis The Journal of Applied Laboratory Medicine 4 (1), 108-119, 2019 | 22 | 2019 |
| Mutations in normal tissues—some diagnostic and clinical implications C Fiala, EP Diamandis BMC medicine 18 (1), 283, 2020 | 21 | 2020 |
| A multi-cancer detection test: focus on the positive predictive value C Fiala, EP Diamandis Annals of Oncology 31 (9), 1267-1268, 2020 | 21 | 2020 |
| Can a broad molecular screen based on circulating tumor DNA aid in early cancer detection? C Fiala, EP Diamandis The Journal of Applied Laboratory Medicine 5 (6), 1372-1377, 2020 | 20 | 2020 |
| The emerging landscape of scientific publishing C Fiala, EP Diamandis Clinical biochemistry 50 (12), 651-655, 2017 | 20 | 2017 |
| Circulating tumor DNA (ctDNA) is not a good proxy for liquid biopsies of tumor tissues for early detection C Fiala, EP Diamandis Clinical Chemistry and Laboratory Medicine (CCLM) 58 (10), 1651-1653, 2020 | 15 | 2020 |
| Cell-free DNA Analysis in Cancer. C Fiala, EP Diamandis The New England journal of medicine 380 (5), 501-501, 2019 | 15 | 2019 |
| Aspirin: Bitter pill or miracle drug? C Fiala, MD Pasic Clinical Biochemistry 85, 1-4, 2020 | 13 | 2020 |
| The democratization of scientific publishing C Fiala, EP Diamandis BMC medicine 17, 1-4, 2019 | 13 | 2019 |
| Can Grail find the trail to early cancer detection? C Fiala, EP Diamandis Clinical Chemistry and Laboratory Medicine (CCLM) 57 (4), 403-406, 2019 | 12 | 2019 |
| How to reduce scientific irreproducibility: the 5-year reflection C Fiala, EP Diamandis Clinical Chemistry and Laboratory Medicine (CCLM) 55 (12), 1845-1848, 2017 | 12 | 2017 |
| Benign and malignant scientific irreproducibility C Fiala, EP Diamandis Clinical Biochemistry 55, 1-2, 2018 | 11 | 2018 |
| Circulating tumor DNA for personalized lung cancer monitoring C Fiala, EP Diamandis BMC medicine 15, 1-3, 2017 | 11 | 2017 |
